AminoArrays
AminoArrays (formerly NanoBioDynamics) is developing next-generation technology for amino acid analysis. Our array-based analyzer represents significant advances in speed, sensitivity, and ease-of-use, all at a lower cost. Applications include protein biochemistry, proteomics, biopharmaceutical manufacturing, clinical diagnostics, and food and animal feed testing.

Cytolution
Cytolution's revolutionary analyzer will take cervical cancer screening to the next level and replace the current widely used manual PAP method. The innovative technology / method will be key to improve screening accuracy and at the same time respond to the growing crisis with cytology laboratory labor shortage while lowering the overall cost of disease management. The CEO and Founder of Cytolution, Urs G. Wiederkehr, has over 20 years of experience in business management in diagnostics with Abbot Diagnostics, Ventana and BioVeris.

Inologic
Inologic is the leading company in the discovery and development of a new class of therapeutics based on inositol signaling molecules - an approach that can generate novel therapeutics for most major diseases. Currently the company, piloted by an experienced leadership team, has compounds in pre-clinical development for the treatment of inflammation and cystic fibrosis. Inologic's drug to treat the underlying cause of cystic fibrosis has received orphan drug designation from the FDA and its development is supported by a $1.5 million award from the Cystic Fibrosis Foundation. Previous to Inologic, the CEO and President, Ed Field, was the President of Molecumetics, where he was instrumental in building the 70-person drug discovery and early-stage development company in Seattle.

Kalinex, Inc.
Kalinex will pioneer the burgeoning chem/biochip industry with its proprietary technology for label-free detection of molecular binding.  This technology is based on 10 years of government funded research by Dr. Arun Majumbar of UC Berkeley and Dr. Thomas Thundat of Oak Ridge National Laboratory.  The Scientific Advisory Board includes Rusty Williams  (Five Prime Therapeutics), former founder of COR Therapeutics and President of Chiron.  This product will address needs in the markets of military/homeland security, industrial control, environment monitoring, drug development and personalized medicine.

Manoa Medical
Manoa Medical is a medical device company created to improve the accuracy of surgical procedures in the breast. Manoa has developed proprietary devices and methods for the minimally invasive excision of lesions and associated diseased ducts. In addition, Manoa has developed a proprietary method of cutting tissue that will not have the problems associated with radiofrequency energized cutting. The CEO and Founder of Manoa Medical, Roberta Lee, is a serial entrepreneur and an MD with a specialty in breast surgery.

Maulikai, Inc.
Maulikai is applying the emergence of synthetic biology to develop innovative economically and environmentally sound solutions to the world’s energy needs.

TheraJect, Inc.
TheraJect's platform technology is positioned to pursue and harvest multiple growth opportunities. TheraJect will focus on research, development, intellectual property creation and protection, and preliminary pre-clinical study. TheraJect's strategy is to earn revenue by licensing and partnering the development of its technology with vaccine, pharmaceutical, biotechnology, medical device, cosmeceuticals, manufacturing, and service provider companies that have the experience and resources to efficiently manage processes outside of our core competencies in pre-clinical product development. This strategy should provide early yet sustainable returns to TheraJect's shareholders.

StrataGent Life Sciences, Inc. / Corium International, Inc.
StrataGent is a specialty drug delivery company developing products for painless, needle-free administration of otherwise injectable drugs. Its products are based on its proprietary microjet technology that delivers large and small therapeutic molecules without a device penetrating into or through the skin. In May of 2004, StrataGent received a $2 million award from the Advanced Technology Program (ATP) at the National Institute of Standards and Technology to support the development of the StrataGent microjet technology. In May 2007 StrataGent announced a $16M Series B financing led by Essex Woodlands Health Ventures. In September 2007, Corium International, Inc., a privately-held transdermal drug delivery company, announced the completion of a $25.1 million Series C financing also led by Essex Woodlands. In connection with the financing, StrataGent merged into Corium. The combined Company will use the proceeds to develop Corium’s pipeline of advanced transdermal products employing its proprietary MicroCorTM microneedle technology and CorplexTM polymer adhesive technology. The Company will also use proceeds to develop products based on StrataGent’s liquid microjet drug delivery technology. Robert Thomas, CEO of StrataGent and former CEO of FoxHollow Technologies, Inc., serves as CEO of the combined company, while Ron Eastman of Essex Woodlands Health Ventures becomes the Company’s chairman. Joining Mr. Eastman on the board of directors are Corium co-founder Gary Cleary and StrataGent co-founder Ravi Srinivasan.

Synvascular, Inc.